bpc+157 Orthopedic Use of BPC-157 BPC-157 Peptide Therapy | Club

The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024

Peptide therapy recommendations must be made on an individual basis after appropriate clinical evaluation

214,215 In clinical trials in subjects with herpes lesions on the lips, a 0.5% topical propolis extract solution was more effective than topical use of the antiviral drug acyclovir for shortening time to healing and reducing symptoms such as pain, burning, itching, tension, and swelling

Ready to take your health and vitality to the next level

Next Step: Book Free Consultation 75% of patients reduced their tinnitus within three months after following our recommendations